GLOW legal status, FDA 503A category, and compounding access.

GLOW legal status: where the FDA 503A category stands now

The GLOW legal status question turns on its injectable peptides, and on the record those peptides are under active FDA review — momentum is real, and access may expand. The anchor for that momentum is concrete: an FDA Pharmacy Compounding Advisory Committee (PCAC) meeting is scheduled for July 23-24, 2026 to discuss several of these peptides as candidates for the Section 503A bulks list ^[14].

That forward motion sits on top of a present-tense fact that has not changed. GLOW's injectable constituents — BPC-157 and TB-500, and GHK-Cu in its injectable form — are currently in FDA's 503A "Category 2," bulk drug substances FDA has identified as potentially presenting significant safety risks. That placement took effect with the September 29, 2023 update to FDA's nominated-substances list, and Category 2 substances are not within FDA's enforcement-discretion policy for 503A compounding ^[12]. In plain terms, compounding-pharmacy access to these peptides is restricted as the record stands today.

Nothing here states that any reclassification has happened. The July 2026 meeting is a scheduled discussion of substances under evaluation — a step in the process, not a decision, a listing, or a dated outcome ^[14].

What "Category 2" means under Sections 503A and 503B

U.S. drug compounding is governed by two sections of the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that may compound larger batches under cGMP-style oversight ^[13].

A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list. Substances not yet listed are evaluated by FDA through a public nomination process. Under FDA's interim policy, Category 1 substances are those that may be eligible for the bulks list and do not raise significant safety risks — FDA does not intend to act against compounding with them while it evaluates. Category 2 substances are those FDA identified as raising significant safety risks; FDA stated it would consider taking action against a compounder for compounding with them ^[12][13]. None of GLOW's three peptides is an FDA-approved drug, which is a separate question from whether a bulk substance may be compounded.

Which GLOW peptides are under FDA review — and which are not

The agenda for the July 23-24, 2026 PCAC meeting is specific, and the distinction matters for GLOW. BPC-157 (as "BPC-157 (free base)" and "BPC-157 acetate") and TB-500 (as "TB-500 (free base)" and "TB-500 acetate") are on that agenda as substances being considered for inclusion on the 503A bulks list — a scheduled evaluation, not a listing decision or a change in current status ^[12][14].

GHK-Cu is not on that agenda. Its injectable form remains in Category 2 on the present record ^[12]. And the copper peptide carries a status split that must be kept separate: topical GHK-Cu, labeled "Copper Tripeptide-1" (INCI), is used as a cosmetic ingredient and is regulated under cosmetics rules, which do not require FDA pre-market approval of the ingredient and have never granted it drug approval ^[15]. The Category 2 restriction applies to GHK-Cu for injectable routes of administration — a different regulatory context from the legal cosmetic ingredient on a skincare label. The two should not be blurred.

How legally compounded peptide access works

Setting the GLOW blend aside, here is how lawful access to a compounded peptide preparation works in general terms — described as the regulatory landscape, not as advice and not as a route to any specific substance.

A compounded medication is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription. Telehealth can serve as the front-end channel for that prescriber evaluation, but it is a route to a licensed-prescriber consultation, not a separate legal status — it does not expand which substances may be compounded or remove the need for a legitimate clinical relationship and a valid prescription ^[13]. The prescription is then dispensed by a state-licensed 503A compounding pharmacy (patient-specific) or, for office or batch use, sourced from an FDA-registered 503B outsourcing facility.

The gating caveat is the ingredient. A compounder may use a requested active ingredient only if it is eligible under the 503A/503B bulk-substance rules — and substances FDA has flagged for significant safety risks are not eligible for routine 503A compounding while that status stands ^[12][13]. That is exactly where GLOW's injectable peptides currently sit. This page does not name any pharmacy, clinic, telehealth provider or vendor, does not provide dosing, and does not describe ways to obtain a restricted substance outside the lawful framework.

Is GLOW legal?

GLOW is not an FDA-approved drug; it is a non-standardized combination of research peptides. Topical Copper Tripeptide-1 is a legal cosmetic ingredient ^[15], but GLOW's injectable peptides — BPC-157, TB-500 and injectable GHK-Cu — are in FDA's 503A Category 2, so compounding access to them is restricted as the record stands ^[12]. BPC-157 and TB-500 are also WADA-prohibited for tested athletes.

Can you get GHK-Cu from a compounding pharmacy?

Injectable GHK-Cu is currently in FDA's 503A Category 2 — identified as potentially presenting significant safety risks and not within FDA's enforcement-discretion policy — so compounding access to it is restricted on the present record ^[12]. That is distinct from topical Copper Tripeptide-1, which is a legal cosmetic ingredient regulated under cosmetics rules ^[15]. This is general information, not legal advice.

What is the FDA 503A status of GLOW?

GLOW's injectable peptides sit in FDA's 503A Category 2, effective with the September 29, 2023 nominated-substances update, restricting compounding access now ^[12]. BPC-157 and TB-500 are on the agenda of a scheduled July 23-24, 2026 PCAC meeting as candidates under evaluation — a discussion, not a decision or a reclassification ^[14]. GHK-Cu is not on that agenda.